Also, a randomized phase II study conducted in Asia to examine the effect of add-on neoadjuvant CRT (capecitabine plus oxaliplatin (CAPOX) therapy plus radiation therapy (RT) at 45 Gy) to surgery plus adjuvant CAPOX therapy [ 9 ] ) showed a trend toward improved disease-free survival (DFS), which was set as the primary endpoint in the neoadjuvant CRT group.
← all excerpts
Clinical practice guidelines for esophagogastric junction cancer: Upper GI Oncology Summit 2023.
1
—
—